SynthesisRespiratory research2026
Outcomes of patients with acute exacerbations of idiopathic pulmonary fibrosis treated with corticosteroids: a systematic review and meta-analysis.
Synthesis in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The Genetic Landscape of Fibrotic Interstitial Lung Diseases: Clinical Implications and Diagnostic Challenges in Familial Pulmonary Fibrosis.Journal of clinical medicine · 2026Review
- Natural therapeutics and traditional formulas targeting macrophage polarization in the fibrotic niche of idiopathic pulmonary fibrosis.Frontiers in immunology · 2026Review
- A biomarker-guided framework for corticosteroid treatment stratification in acute exacerbation of idiopathic pulmonary fibrosis.Frontiers in pharmacology · 2026Article
- Development of interpretable machine learning models for predicting the probability of sepsis in patients with pulmonary fibrosis in the intensive care unit: based on MIMIC-IV and multi-database validation.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute exacerbation of idiopathic pulmonary fibrosis (IPF) is the most severe complication and one of the main causes of death in these patients. No proven effective therapies have been reported until now but high-dose corticosteroids are suggested by the international guidelines.
methodsA search of the scientific evidence was carried out using PubMed, Embase, and Scopus. Observational and experimental studies describing clinical outcomes in adult patients with acute exacerbations of IPF treated with corticosteroids were included.
results32 studies were selected for the qualitative and quantitative analysis. In patients treated only with corticosteroids, the pooled 90-day and in-hospital mortality rate was 42% (95% CI = 19-67%) and 43% (95% CI = 30-56%), respectively. Pooled 90-day mortality in patients treated with methylprednisolone at doses of 1000 mg/day was higher than in those treated with 500-1000 mg/day (i.e. 10 mg/kg/day) (54% (95% CI = 11-94%) VS. 39% (95% CI = 12 to 71%)). In patients with background antifibrotic therapy, the pooled 90-days mortality was of 39% (95% CI = 25-54%) while in those without was of 49% (95% CI = 10-89%). The 90-day and in -hospital mortality for patients receiving concomitant immunosuppressive therapy was 37% (95% CI = 29-46%) and 35% (95% CI = 12-62%), respectively. The overall 1-year mortality was 43% (95%CI = 30-56%).
conclusionsPatients with acute exacerbation of IPF treated with corticosteroids show a high short- and long-term mortality. Those treated with lower steroid doses and with background antifibrotic therapy show the highest short-term survival rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.